Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
NCT ID: NCT03005769
Last Updated: 2017-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
262 participants
OBSERVATIONAL
2016-12-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data from each patient will be collected after informed consent is signed (inclusion visit), and will include retrospective information from the start of aripiprazole once-monthly treatment initiation (index date) until the follow-up/inclusion visit (minimum of 6 months after the index date). Data will be retrospectively collected from all visits occurring as per clinical practice (usually once monthly).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
NCT03130478
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
NCT03130465
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
NCT00237939
Effect on Cognitive Function of a Treatment With Aripiprazole
NCT00329810
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00325689
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female
3. Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5), available at start of aripiprazole once-monthly treatment, and confirmed by the current investigator
4. Aripiprazole once-monthly initiation (at least 1 injection) according to the clinical practice, at least 6 months before the inclusion and on June 1st 2015 or at a later date (index date)
5. Aripiprazole once-monthly was the main antipsychotic at the time of treatment initiation
6. Willingness to participate in the study; subjects must give their written consent to participate
Exclusion Criteria
2. Participation in a clinical trial during the retrospective follow-up period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka Pharmaceutical Europe Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Department
Role: STUDY_DIRECTOR
Otsuka Europe
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Salute Mentale
Ancona, , Italy
SPDC ASST Spedali Civili
Brescia, , Italy
Azienda Ospedaliero-Universitaria di Cagliari
Cagliari, , Italy
Policlinico "G. Rodolico"
Catania, , Italy
Policlinico Mater Domini
Catanzaro, , Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Casa Di Cura Neuropsichiatrica Villa Von Siebenthal
Genzano di Roma, , Italy
Ospedale Maria S.S. dello splendore
Giulianova, , Italy
ASL Lecce
Lecce, , Italy
ASST Grande Ospedale Metropolitano
Milan, , Italy
Azienda Ospedaliera Fatebenefratelli e Oftalmico
Milan, , Italy
Ospedale San Gerardo
Monza, , Italy
SCDU Psichiatria. AOU San Luigi Gonzaga
Orbassano, , Italy
Azienda Ospedaliera di Padova
Padua, , Italy
Clinica Psichiatrica. Università di Palermo
Palermo, , Italy
Università degli Studi di Perugia
Perugia, , Italy
Centro di Salute Mentale
Pomezia, , Italy
ASL Salerno
Pontecagnano, , Italy
Azienda Ospedaliera Universitaria Senese
Siena, , Italy
Azienda ULSS 9 Treviso
Treviso, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
031-306-00108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.